Boehringer Mannheim Offering Diversa's Novel Enzymes.LONDON--(BW HealthWire)--Sept. 16, 1997--Boehringer Mannheim and Diversa Corporation (formerly Recombinant BioCatalysis(TM) Inc.) today announced the availability of certain Diversa Corp. enzymes as part of the enzyme product line offered by Boehringer Mannheim. The announcement was made today at the CPhI '97 Pharmaceutical Ingredients Show in London. Dieter Lingelbach, Vice President, Industrial Biochemicals, Boehringer Mannheim, stated that with this step, "Boehringer Mannheim is enlarging ENLARGING. Extending or making more comprehensive; as an enlarging statute, which is one extending the common law. its range of enzymes to be used as biocatalysts in chemical and pharmaceutical manufacturing, and intensifying its relationship with Diversa to market Diversa's novel enzymes for these applications." Boehringer Mannheim has recently been entering into a number of very promising partnerships with its pharmaceutical and industrial customers, where these customers are employing modern enzymes in their processes. Lingelbach added: "With the use of these enzymes These Enzymes is an American hardcore/punk band featuring members of the All-American Rejects and Sons of Abraham. Biography These Enzymes was formed in late 2003 by All-American Rejects members Mike Kennerty (guitar) and Chris Gaylor (drums) along with former Sons of customers are achieving substantial advantages over chemical routes, and thereby realizing significant manufacturing cost savings because of higher yields and fewer problems associated with handling, separation and disposal of unwanted by-products." He continued: "We are pleased to add Diversa's unique enzymes to our line and believe they will enhance our ability to meet our customer's needs." "Diversa's robust enzymes are in demand for pharmaceutical and industrial applications which need enzymes that operate in aggressive conditions, such as extremes of pH, temperature or the presence of solvents," said Donald C. Garaventi, President of Diversa. "The unique activity and stability of these enzymes provide improved manufacturing processes, with higher quality and lower costs." "The addition of our enzymes to the Boehringer Mannheim product line is an important step forward for Diversa," Garaventi added. "Boehringer Mannheim has a strong global sales and marketing capability that reaches the key people in important pharmaceutical and industrial markets. We believe that Boehringer Mannheim, Diversa and their customers will greatly benefit from this new initiative." A long-term, non-exclusive agreement between Boehringer Mannheim and Diversa was signed in the latter part of 1996. Since that time the companies have worked closely to finalize fi·nal·ize tr.v. fi·nal·ized, fi·nal·iz·ing, fi·nal·iz·es To put into final form; complete or conclude: "They have jointly agreed ... all details relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc the enzymes which would initially be offered, literature, technical support information, supply and packaging matters. Boehringer Mannheim, a high technology company in the healthcare market, is a leading manufacturer of enzymes for diagnostic use, research biochemicals and industrial biochemicals. It is continuously expanding its range of biocatalysts. In order to develop the biocatalysis market further, Boehringer Mannheim has entered into strategic partnerships with Diversa and, in 1995, with Novo Nordisk Wikipedia is not the place for advertisement or self-advertising. Novo Nordisk (, NYSE: NVO) manufactures and markets pharmaceutical products and services. Founded in Denmark in 1923, the company has since become a world leader in diabetes care with the broadest . Boehringer Mannheim has a leading position in research and development of new drugs, diagnostics and biochemicals. Biotechnology is a prominent component of the company profile. Boehringer Mannheim operates one of Europe's largest biotechnology facilities in Penzberg, Bavaria. The core competencies A core competency is something that a firm can do well and that meets the following three conditions specified by Hamel and Prahalad (1990):
Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. are diabetes mellitus diabetes mellitus Disorder of insufficient production of or reduced sensitivity to insulin. Insulin, synthesized in the islets of Langerhans (see Langerhans, islets of), is necessary to metabolize glucose. In diabetes, blood sugar levels increase (hyperglycemia). , cardiovascular diseases Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease , oncology, lipid and bone metabolism It is a common misconception that bones are static in nature and hardly change once an individual becomes an adult. On the contrary, bones are continuously undergoing a dynamic process of resorption and deposition known as bone metabolism. disorders. Diversa is the world leader in the discovery, modification and manufacture of novel enzymes. Since 1994 it has discovered more than 350 proprietary enzymes which exceeds the total number available from all other suppliers. It currently has customers world-wide and has entered into four strategic alliances. Founded in 1994, the Company was formerly known as Recombinant BioCatalysis(TM) Inc. CONTACT: Diversa Corporation Donald Garaventi, 619/453-7020 or Mentus, Inc. Linda Seaton, 619/455-5500 |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion